Iterum Therapeutics earnings were -$22.6M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ITRM earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$4.9M, down 25.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ITRM reported annual earnings of -$24.8M, with -35.4% growth.
Iterum Therapeutics Earnings Reports & History FAQ
What were Iterum Therapeutics's earnings last quarter?
Iterum Therapeutics (NASDAQ: ITRM) reported Q1 2025 earnings per share (EPS) of -$0.14, up 69.57% year over year. Total ITRM earnings for the quarter were -$4.89 million. In the same quarter last year, Iterum Therapeutics's earnings per share (EPS) was -$0.46.
Is Iterum Therapeutics profitable or losing money?
As of the last Iterum Therapeutics earnings report, Iterum Therapeutics is currently losing money. Iterum Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$22.56 million, a 36.59% decrease year over year.
What was ITRM's earnings growth in the past year?
As of Iterum Therapeutics's earnings date in Q2 2025, Iterum Therapeutics's earnings has grown year over year. ITRM earnings in the past year totalled -$22.56 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.